Development of oral cladribine for the treatment of multiple sclerosis.

Journal of Neurology
H P HartungGiancarlo Comi Giancarlo Comi

Abstract

Multiple sclerosis (MS) is a chronic immune-mediated disorder of the CNS in which autoreactive CD4+ and CD8+ T lymphocytes, B lymphocytes, antibodies, macrophages and cytokines synergize to attack myelin sheaths and injure underlying axons. Current disease-modifying drugs (DMDs) for MS require regular and frequent parenteral administration and are associated with limited long-term treatment adherence. Of all the potential new oral MS agents in development, cladribine is the only therapy with the potential for short-course dosing. Cladribine is an immunosuppressant that offers targeted, sustained regulation of the immune system and that has a well-characterized safety profile, derived from more than 15 years of use of the parenteral formulation in oncology indications and MS. This paper discusses the need for new MS therapies to improve treatment adherence, and reviews the mechanism of action, existing efficacy and safety data, and the clinical development of oral cladribine. The need for continuous risk monitoring for all new potent immunoactive drugs under development is emphasized. Preliminary results of the 96-week, double-blind, randomized, placebo-controlled, multicenter CLARITY (CLAdRIbine Tablets Treating MS OrallY) stud...Continue Reading

References

Dec 1, 1977·Proceedings of the National Academy of Sciences of the United States of America·D A CarsonJ E Seegmiller
Oct 17, 1992·Lancet·E Beutler
Nov 1, 1994·Annals of Hematology·H J GuchelaarM R Schaafsma
Jan 1, 1994·Acta Haematologica·E BeutlerC J Carrera
Jan 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R A LarsonM J Ratain
Feb 20, 1996·Proceedings of the National Academy of Sciences of the United States of America·E BeutlerJ Zyroff
Jul 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G JuliussonJ Liliemark
Jan 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G LiuE Warner
Feb 1, 1997·Clinical Pharmacokinetics·J Liliemark
May 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R KurzrockM Talpaz
Jan 1, 1997·Scandinavian Journal of Rheumatology·M SchirmerG Konwalinka
Jan 20, 1999·Proceedings of the Association of American Physicians·J S RomineE Beutler
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonB Freidlin
Sep 28, 2000·The New England Journal of Medicine·J H NoseworthyB G Weinshenker
Aug 21, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·V E Stone
Dec 11, 2002·JAMA : the Journal of the American Medical Association·Heather P McDonaldR Brian Haynes
Dec 31, 2002·Lancet·Hans-Peter HartungUNKNOWN Mitoxantrone in Multiple Sclerosis Study Group (MIMS)
Apr 6, 2004·Leukemia & Lymphoma·Robert Z Orlowski
Aug 13, 2004·Proceedings of the National Academy of Sciences of the United States of America·Reinhard Hohlfeld, Hartmut Wekerle
Jun 17, 2005·Multiple Sclerosis : Clinical and Laboratory Research·Jordi RíoXavier Montalban
Oct 7, 2005·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Michel Chofflon
Oct 22, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L FallowfieldM Price
Jan 31, 2006·Acta Neurologica Scandinavica·J A CramerM Glassman
Mar 3, 2006·The New England Journal of Medicine·Elliot M FrohmanCedric S Raine
Mar 4, 2006·BMJ : British Medical Journal·T J Murray
Jul 5, 2006·The Journal of Neuroscience Nursing : Journal of the American Association of Neuroscience Nurses·Darcy Cox, Jerome Stone
Jul 13, 2006·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·M PugliattiI Milanov
Aug 29, 2006·Journal of Neuroimmunology·Jack Antel, Amit Bar-Or
Sep 21, 2006·The Annals of Pharmacotherapy·Julie A BrousilAmanda L Schlein
Feb 14, 2007·Clinical Therapeutics·Margaret E Kruk, Nina Schwalbe
Mar 29, 2007·Brain Pathology·Hans LassmannClaudia F Lucchinetti
Sep 6, 2007·International Journal of Clinical Practice·B A Cohen, P Rieckmann
Oct 31, 2007·Annals of Neurology·Bernhard Hemmer, Hans-Peter Hartung
Dec 1, 2007·Clinical Interventions in Aging·Jean-Yves Reginster, Véronique Rabenda
Jun 17, 2008·Current Opinion in Neurology·Michael K Racke
Apr 22, 2008·The Cochrane Database of Systematic Reviews·R B HaynesX Yao

❮ Previous
Next ❯

Citations

Aug 7, 2010·Drug Design, Development and Therapy·Clemens WarnkeBernd C Kieseier
Mar 6, 2013·Drug, Healthcare and Patient Safety·Jan Thöne, Gisa Ellrichmann
Mar 26, 2011·Journal of Neurology·Martin DuddyRalf Gold
Dec 7, 2010·Neurología : publicación oficial de la Sociedad Española de Neurología·J M García Domínguez, J Guzmán de Villoria Lebiedziejewski
Jun 19, 2010·Progress in Neurobiology·Eilhard MixUwe K Zettl
Dec 22, 2012·Expert Opinion on Pharmacotherapy·Giancarlo ComiMatthew Scaramozza
Jul 10, 2013·Journal of the Neurological Sciences·Krystyna Mitosek-SzewczykJacek Rolinski
Jan 1, 2012·Journal of Central Nervous System Disease·Teri L Schreiner, Augusto Miravalle
Jan 30, 2015·Journal of Clinical Neurology·Woojun KimHo Jin Kim
Jan 19, 2011·Clinical Neuropharmacology·Thomas P Leist, Robert Weissert
Jun 17, 2010·Nature Reviews. Neurology·Orhan AktasHans-Peter Hartung
Oct 21, 2017·Multiple Sclerosis Journal - Experimental, Translational and Clinical·Mark S FreedmanFernando Dangond
Sep 1, 2018·Neurology and Therapy·Yara Dadalti FragosoClaudia Cristina F Vasconcelos
May 25, 2020·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Gavin GiovannoniStuart Cook
Jun 23, 2015·Expert Review of Neurotherapeutics·Emanuele D'AmicoFrancesco Patti
Jan 21, 2020·Chinese Journal of Natural Medicines·Qian-Wen LiWei Guo

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Proceedings of the National Academy of Sciences of the United States of America
E BeutlerJ Zyroff
The New England Journal of Medicine
Gavin GiovannoniCLARITY Study Group
© 2022 Meta ULC. All rights reserved